Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tauns LaboratoriesTSE:197A +1.90%15 EPS without NRI is 円1.78 as of Dec. 2025. GuruFocus rates TSE:197A with a GF Score™ of 15/100. The stock has 6 warning signs investors should review. Among 660 Medical Devices & Instruments companies, Tauns Laboratories ranks worse than 68.64% on this metric.
Tauns Laboratories's earnings per share without non-recurring items for the
three
months ended in Dec. 2025 was 円0.00.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 円1.78.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Tauns Laboratories's EPS without NRI or its related term are showing as below:
TSE:197A'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.4 Med: -5.4 Max: -5.4
Current: -5.4
During the past 4 years, Tauns Laboratories's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -5.40% per year. The lowest was -5.40% per year. And the median was -5.40% per year.
TSE:197A's 3-Year EPS without NRI Growth Rate is ranked worse than 68.64% of 660
companies
in the Medical Devices & Instruments industry
Industry Median: 8.25
vs TSE:197A: -5.40
Tauns Laboratories's EPS (Basic) for the
three
months ended in Dec. 2025 was 円0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was 円3.50.
Tauns Laboratories (TSE:197A) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Tauns Laboratories EPS without NRI Related Terms
Tauns Laboratories EPS without NRI Historical Data
* Premium members only.
The historical data trend for Tauns Laboratories's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:197A vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, Tauns Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauns Laboratories PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Tauns Laboratories's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauns Laboratories (TSE:197A) has a EPS without NRI of 円1.78 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Tauns Laboratories and its competitors. According to the industry distribution chart, Tauns Laboratories ranks #453 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 68.6%.
Is Tauns Laboratories' EPS without NRI too high?
Tauns Laboratories' current EPS without NRI is 円1.78. Based on the distribution chart, Tauns Laboratories ranks #453 out of 660 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tauns Laboratories has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tauns Laboratories ranks #453 out of 660 companies for EPS without NRI. This places Tauns Laboratories in the lower half of its industry. The industry median EPS without NRI is 8.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.25, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Tauns Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tauns Laboratories's current EPS without NRI is 円1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current EPS without NRI of 円1.78. The current EPS without NRI is 円1.78. Tauns Laboratories' overall GF Score™ is 15/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current EPS without NRI is 円1.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
15GF Score
Get the complete analysis for TSE:197A
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:197A has been successfully added to your 
